Our own network of specialised service-provider companies allows us to carry out projects in a way that offers the client the advantage of specialisation and the flexibility of a personalised service as well as the strength of a group with centralised project management. The result for the client is a combination of dedication and flexibility throughout the project.
Services
Our four areas of activity
Early Drug Discovery
- Target Identification & Validation
- Hit Discovery
- Assay Development & Screening
- High Throughput Screening
- Hit to Lead
- Lead Optimisation
Preclinical Studies
- In Vivo, In Vitro & Ex Vivo Assays
- ADME
- Proof of Concept
- Drug Delivery
- Formulation Optimisation & Bioavailability
- Dose Range Finding
- IND-enabling Studies
- IND Application
Clinical Development
- Phase I – Healthy Volunteer Study
- Phase II and Phase III – Studies in Patient Populations
- Dose Escalation, Single Ascending & Multiple Dose Studies
- Safety & Efficiancy
- Pharmacokinetic Analysis
- Bionanalytical Method Development & Validation
- Marketing & Health Economics
Preclinical Studies
- In Vivo, In Vitro & Ex Vivo Assays
- ADME
- Proof of Concept
- Drug Delivery
- Formulation Optimisation & Bioavailability
- Dose Range Finding
- IND-enabling Studies
- IND Application
Regulatory & Registration
- Regulatory Strategy
- Scientific Advice
- Clinical Protocol Design
- Orphan Drug Applications
- Regulatory and Medical Writing
- Development of Investigationals Medicinal Product Dossier (IMPD)
- Paediatric Investigation Plan (PIP)
- Regulatory Submission Management
About Drug Discovery Innovation Programme 2022
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2022 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2022 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.